As filed with the Securities
and Exchange Commission on December 17, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Vicarious Surgical Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
87-2678169
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
78 Fourth Avenue
Waltham, Massachusetts 02451
Telephone: (617) 868-1700
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
2021 Equity Incentive Plan
(Full Title of the Plan)
Adam Sachs
Chief Executive Officer
Vicarious Surgical Inc.
78 Fourth Avenue
Waltham, Massachusetts 02451
Telephone: (617) 868-1700
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Edwin C. Pease, Esq.
Andrew D. Thorpe, Esq.
Melissa V. Frayer, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.
One Financial Center
Boston, Massachusetts 02111
Telephone: (617) 542-6000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging
growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☒
|
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
|
|
Amount
to be
Registered
(1)
|
|
Proposed
Maximum
Offering
Price
Per Share
|
|
Proposed
Maximum
Aggregate
Offering Price
(2)
|
|
Amount of
Registration
Fee
|
Class A common stock, par value $0.0001 per share
|
|
|
4,828,699
|
|
|
(2
|
)
|
$
|
22,135,146.76
|
|
$
|
2,051.93
|
|
(1)
|
The number of shares of Class
A common stock, par value $0.0001 per share (“Class A common stock”), stated above consists of the aggregate number
of shares which may be sold upon the exercise of options, or the settlement of restricted stock units under the 2021 Equity Incentive
Plan (the “2021 Plan”). The shares of Class A common stock registered hereunder for issuance pursuant to the 2021
Plan consist of up to 4,828,699 shares currently reserved for issuance pursuant to the 2021 Plan. Pursuant to Rule 416(a) under the Securities
Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares
of the Registrant’s Class A common stock that become issuable under the 2021 Plan by reason of any stock dividend, stock split,
recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number
of outstanding shares of Class A common stock.
|
|
(2)
|
Estimated solely for the purpose
of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering
price per share and the aggregate offering price for shares reserved for future issuance under the 2021 Plan are based on (i) in the
case of shares of Class A common stock which may be purchased upon exercise of outstanding options, the fee is calculated on the basis
of the price at which the options may be exercised; and (ii) in the case of shares of Class A common stock not yet issued and subject
to stock-based awards, the average of the high and the low price of Registrant’s Class A common stock as reported on the New York
Stock Exchange on December 10, 2021. The chart below details the calculations of the registration fee:
|
Securities
|
|
Number of
Shares
|
|
|
Offering
Price Per
Share
|
|
|
Aggregate
Offering Price
|
|
Shares underlying restricted stock units under the 2021 Plan
|
|
|
652,130
|
|
|
$
|
9.99
|
(2)
|
|
$
|
6,514,778.70
|
|
Shares underlying outstanding option awards under the 2021 Plan
|
|
|
4,176,569
|
|
|
$
|
3.74
|
(2)
|
|
$
|
15,620,368.06
|
|
Proposed Maximum Aggregate Offering Price
|
|
|
|
|
|
|
|
|
|
$
|
22,135,146.76
|
|
Registration Fee
|
|
|
|
|
|
|
|
|
|
$
|
2,051.93
|
|
EXPLANATORY NOTE
This Registration Statement
on Form S-8 (this “Registration Statement”) includes a reoffer prospectus (the “Reoffer Prospectus”)
prepared in accordance with General Instruction C to Form S-8 and in accordance with the requirements of Part I of Form S-3. This
Reoffer Prospectus may be used for reoffers and resales of shares of Class A common stock, par value $0.0001 per share (the “Class
A common stock”), of Vicarious Surgical Inc. (the “Registrant,” “we,” “us”
or “our”) f/k/a D8 Holdings Corp., our legal predecessor and a special purpose acquisition company (“D8”),
on a continuous or delayed basis that may be deemed to be “restricted securities” or “control securities” under
the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder,
that are issuable to certain stockholders that are current executive officers and directors of the Registrant identified in the Reoffer
Prospectus (the “selling securityholders”). The number of shares of Class A common stock included in the Reoffer Prospectus
represents shares of Class A common stock acquired by or issuable to the selling securityholders pursuant to equity awards and does not
necessarily represent an intention to sell any or all of such shares of Class A common stock. As specified in General Instruction C of Form S-8, the amount
of securities to be reoffered or resold by means of the Reoffer Prospectus by each selling securityholder, and any other person with whom
he or she is acting in concert for the purpose of selling the Registrant’s securities, may not exceed, during any three-month period,
the amount specified in Rule 144(e) under the Securities Act.
On September 17, 2021, the
Registrant completed its business combination with what was then known as Vicarious Surgical Inc. (“Legacy Vicarious”)
in accordance with the terms of the Business Combination Agreement, dated as of April 15, 2021 (the “Business Combination Agreement”),
by and among the Registrant, Snowball Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Legacy Vicarious,
pursuant to which Merger Sub merged with and into Legacy Vicarious, with Legacy Vicarious surviving as a wholly owned subsidiary of the
Registrant (the “Merger”). In connection with the Merger, the Registrant changed its name to “Vicarious Surgical
Inc.” and Legacy Vicarious changed its name to “Vicarious Surgical Operating Co.” On October 6, 2021, Legacy Vicarious
changed its name from “Vicarious Surgical Operating Co.” to “Vicarious Surgical US Inc.”
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.
The documents containing the information in Part I relating to the
2021 Plan will be sent or given to participants in the 2021 Plan as specified by Rule 428(b)(1) promulgated under the Securities Act.
In accordance with the instructions to Part I of Form S-8, such documents will not be filed with the Commission either as part of this
registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents
and the documents incorporated by reference pursuant to Item 3 of Part II of this registration statement, taken together, constitute the
prospectus (the “Section 10(a) Prospectus”) as required by Section 10(a) of the Securities Act in respect of future issuances
under the 2021 Plan.
Item 2. Registrant Information and Employee Plan Annual Information.
Upon written or oral request, any of the documents incorporated by
reference in Item 3 of Part II of this registration statement, which are also incorporated by reference in the Section 10(a) Prospectus,
other documents required to be delivered to eligible participants pursuant to Rule 428(b), or additional information about the 2021 Plan,
will be available without charge by contacting Vicarious Surgical Inc., Attention: Legal Department, 78 Fourth Avenue, Waltham, Massachusetts
02451, (617) 868-1700.
REOFFER PROSPECTUS
Vicarious Surgical, Inc.
4,828,699 Shares of Class A Common Stock
This reoffer prospectus (“Reoffer
Prospectus”) relates to the offer and sale from time to time by the selling stockholders named in this Reoffer Prospectus (the
“selling securityholders”), or their permitted transferees, of up to 4,828,699 shares (the “Shares”)
of Class A common stock, par value $0.0001 per share (“Class A common stock”), of Vicarious Surgical Inc. (the
“Company”). This Reoffer Prospectus covers the Shares that will be acquired by or issuable to the selling securityholders
pursuant to a stock option agreement or restricted stock unit agreement, as applicable, between the Company and such selling securityholder
under the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the “2021 Plan”). We are not offering any of the Shares
and will not receive any proceeds from the sale of the Shares by the selling securityholders made hereunder. The selling securityholders
are certain of our current executive officers and directors, all of whom may be deemed to be an “affiliate” of our company
(as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”)).
Subject to the satisfaction
of any conditions to vesting of the shares of Class A common stock offered hereby pursuant to the terms of the relevant award agreements,
the selling securityholders may sell the Shares described in this Reoffer Prospectus in a number of different ways and at varying prices,
including sales in the open market, sales in negotiated transactions, and sales by a combination of these methods. The selling securityholders
may sell any, all, or none of the Shares and we do not know when or in what amount the selling securityholders may sell their Shares hereunder
following the effective date of this registration statement. The price at which any of the Shares may be sold, and the commissions, if
any, paid in connection with any such sale, are unknown and may vary from transaction to transaction. The Shares may be sold at the market
price of the Class A common stock at the time of a sale, at prices relating to the market price over a period of time, or at prices negotiated
with the buyers of shares. The Shares may be sold through underwriters or dealers which the selling securityholders may select. If underwriters
or dealers are used to sell the Shares, we will name them and describe their compensation in a prospectus supplement. We provide more
information about how the selling securityholders may sell their Shares in the section titled “Plan of Distribution.”
The selling securityholders will bear all sales commissions and similar expenses. Any other expenses incurred by us in connection with
the registration and offering that are not borne by the selling securityholders will be borne by us. We are registering the offer and
sale of the Shares to satisfy certain registration rights we have granted.
Our Class A common stock is
listed on the New York Stock Exchange (“NYSE”) under the symbol “RBOT.” On December 16, 2021, the last
quoted sale price for our Class A common stock as reported on NYSE was $10.76.
The amount of the Shares to
be offered or resold under this Reoffer Prospectus by each selling securityholder, or other person with whom he or she is acting in concert
for the purpose of selling our securities, may not exceed, during any three-month period, the amount specified in Rule 144(e) under the
Securities Act.
We are an “emerging
growth company” and a “smaller reporting company” as defined under the U.S. federal securities laws, and, as such, we
have elected to comply with certain reduced public company reporting requirements for this Reoffer Prospectus and may elect to do so in
future filings.
The Securities Exchange Commission
(the “SEC” or the “Commission”) may take the view that, under certain circumstances, the selling
securityholders and any broker-dealers or agents that participate with the selling securityholders in the distribution of the Shares may
be deemed to be “underwriters” within the meaning of the Securities Act. Commissions, discounts or concessions received by
any such broker-dealer or agent may be deemed to be underwriting commissions under the Securities Act. See the section titled “Plan
of Distribution.”
Investing in our securities
involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our
securities in the section titled “Risk Factors” beginning on page 3 of this Reoffer Prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this Reoffer Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Reoffer
Prospectus is December 17, 2021.
TABLE OF CONTENTS
ABOUT THIS REOFFER
PROSPECTUS
This Reoffer Prospectus contains
important information you should know before investing, including important information about our company and the Shares being offered.
You should carefully read this Reoffer Prospectus, as well as the additional information contained in the documents described under “Where
You Can Find More Information” and “Incorporation of Certain Information by Reference” in this Reoffer Prospectus, and
in particular the periodic and current reporting documents we file with the SEC. You should rely only on the information contained
in this Reoffer Prospectus or incorporated herein by reference or in any accompanying prospectus supplement by us or on our behalf. We
have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not making an offer to sell the Shares in any jurisdiction where the offer or sale is not
permitted. You should assume that the information appearing in this Reoffer Prospectus is accurate only as of the date hereof. Additionally,
any information we have incorporated by reference in this Reoffer Prospectus is accurate only as of the date of the document incorporated
by reference, regardless of the time of delivery of this Reoffer Prospectus or any sale of securities. Our business, financial condition,
results of operations and prospects may have changed since those dates.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Reoffer Prospectus
includes forward-looking statements regarding, among other things, our plans, strategies and prospects, both business and financial.
These statements are based on our management’s beliefs and assumptions. Although we believe that our plans, intentions and expectations
reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize
these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions.
Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies,
events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the
words “believes”, “estimates”, “expects”, “projects”, “forecasts”, “may”,
“will”, “should”, “seeks”, “plans”, “scheduled”, “anticipates”
or “intends” or similar expressions. Forward-looking statements contained in this Reoffer Prospectus include, but are
not limited to, statements about:
|
●
|
the ability to recognize the anticipated benefits of the Business
Combination, which may be affected by, among other things, competition and our ability to grow and manage growth profitably and retain
our key employees;
|
|
●
|
the ability to maintain the listing of our Class A common
stock on the NYSE;
|
|
●
|
the success, cost and timing of our product and service development
activities;
|
|
●
|
the commercialization and adoption of our initial products
and the success of the Vicarious System and any of our future product and service offerings;
|
|
●
|
the potential attributes and benefits of the Vicarious System
and any of our other product and service offerings once commercialized;
|
|
●
|
our ability to obtain and maintain regulatory approval for
the Vicarious System and our product and service offerings, and any related restrictions and limitations of any approved product or service
offering;
|
|
●
|
our business is subject to a variety of U.S. and foreign laws,
which are subject to change and could adversely affect our business;
|
|
●
|
our ability to identify, in-license or acquire additional
technology;
|
|
●
|
our ability to maintain our existing license agreements and
manufacturing arrangements;
|
|
●
|
our ability to compete with other companies currently marketing
or engaged in the development of products and services for ventral hernia repair and additional surgical applications, many of which
have greater financial and marketing resources than us;
|
|
●
|
the size and growth potential of the markets for the Vicarious
System and any of our future product and service offerings, and the ability of each to serve those markets once commercialized, either
alone or in partnership with others;
|
|
●
|
our estimates regarding expenses, future revenue, capital
requirements and needs for additional financing;
|
|
●
|
our ability to raise financing in the future;
|
|
●
|
our financial performance;
|
|
●
|
our intellectual property rights and how failure to protect
or enforce these rights could harm our business, results of operations and financial condition
|
|
●
|
economic downturns and political and market conditions beyond
our control and their potential to adversely affect our business, financial condition and results of operations;
|
|
●
|
the anticipated continued impact of the COVID-19 pandemic
on our business; and
|
|
●
|
other factors detailed under the section titled “Risk
Factors.”
|
SUMMARY OF THE PROSPECTUS
This summary highlights
information contained in greater detail elsewhere in this Reoffer Prospectus. This summary does not contain all of the information you
should consider in making your investment decision. You should read the entire Reoffer Prospectus carefully before making an investment
in our securities. You should carefully consider, among other things, our consolidated financial statements and the related notes and
the sections titled “Risk Factors,” “Business,” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” incorporated by reference in this Reoffer Prospectus. Unless the context otherwise requires,
we use the terms “Vicarious,” the “Company,” “we,” “us” and “our” in this
Reoffer Prospectus to refer to Vicarious Surgical Inc. and our wholly owned subsidiaries.
The Company
We
are combining advanced miniaturized robotics, computer science and 3D visualization to build an intelligent and affordable, single-incision surgical
robot, called the Vicarious System, that virtually transports surgeons inside the patient to perform minimally invasive surgery, or MIS. With
our disruptive next-generation robotics technology, we are seeking to increase the efficiency of surgical procedures, improve patient
outcomes and reduce healthcare costs. We believe that the Vicarious System is the only surgical robotic system to receive a “Breakthrough
Device” designation from the U.S. Food and Drug Administration, or the FDA, for ventral hernia procedures. A Breakthrough Device
designation offers multiple benefits designed to accelerate the timeline to market for novel medical devices, including priority review
of the pre-market submission for the device, and an established pathway to Centers for Medicare & Medicaid Services, or
CMS, reimbursement and coverage. However, the process of medical device development is inherently uncertain and there is no guarantee
that a Breakthrough Device designation will accelerate the timeline for approval or make it more likely that the Vicarious System will
be approved. Led by a visionary team of engineers from the Massachusetts Institute of Technology, or MIT, we intend to deliver the next
generation in robotic-assisted surgery, designed to solve the shortcomings of open surgery, and current laparoscopic and robot-assisted MIS. We
have developed multiple prototypes and intend to request a pre-submission meeting with the FDA by the end of 2021 and to file a 510(k) application
for the Vicarious System for ventral hernia procedures by the end of 2023, and other indications thereafter.
Background and Business Combination
On September 17, 2021
(the “Closing Date”), D8 Holdings Corp., a Delaware corporation that was previously a Cayman Islands exempted company
that migrated to and domesticated as described below (“D8” and after the Business Combination described herein, the
“Company”), consummated the previously announced business combination (the “Business Combination”)
pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2021 (the “Business Combination Agreement”),
by and among D8, Snowball Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Vicarious Surgical Inc., a Delaware
corporation (“Legacy Vicarious”) and Adam Sachs, in his capacity as the stockholder representative.
Prior to the Closing Date,
on September 16, 2021, as contemplated by the Business Combination Agreement, D8 filed a notice of deregistration and necessary accompanying
documents with the Cayman Islands Registrar of Companies, and a certificate of incorporation and a certificate of corporate domestication
with the Secretary of State of the State of Delaware, under which D8 was domesticated and continues as a Delaware corporation, changing
its name to “Vicarious Surgical Inc.” (the “Domestication”). As a result of and upon the effective time
of the Domestication, (a) each D8 Unit then issued and outstanding as of immediately prior to the Domestication automatically separated
into the underlying D8 Class A ordinary share and one-half of a D8 Public Warrant, (b) each D8 Class A ordinary share
issued and outstanding immediately prior to the Domestication remained outstanding and automatically converted into one share of Class A
common stock, (c) each D8 Class B ordinary share, par value $0.0001 per share, of D8 issued and outstanding immediately prior
to the Domestication automatically converted into one share of D8 Class A ordinary share, and (d) each D8 Public Warrant automatically
converted into a Public Warrant on the same terms as the D8 Public Warrants. No fractional Public Warrants were issued upon separation
of the D8 Units.
On September 17, 2021,
concurrently with the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement
(such completion, the “Closing”), D8 changed its name to “Vicarious Surgical Inc.” (“Vicarious
Surgical”) and Legacy Vicarious changed its name to “Vicarious Surgical Operating Co.” On October 6, 2021,
Legacy Vicarious changed its name from “Vicarious Surgical Operating Co.” to “Vicarious Surgical US Inc.”
As a consequence of the
Business Combination, each D8 Class B ordinary share or that was issued and outstanding as of immediately prior to the effective
time of the Merger (the “Effective Time”) was converted, on a one-for-one basis, into a share of Class A
common stock. The Business Combination had no effect on the Class A common stock that was issued and outstanding as of immediately
prior to the Effective Time, which continues to remain outstanding, except for the shares redeemed in connection with the Business Combination.
In connection with the
Closing of the Business Combination, (i) Legacy Vicarious stockholders received shares of Vicarious Surgical Class A common
stock equal to the amount of shares of Legacy Vicarious capital stock owned by such stockholder multiplied by 3.29831 for each share in
such class of Legacy Vicarious capital stock that was issued and outstanding immediately prior to the Effective Time, rounded to the nearest
whole number of shares; (ii) the Legacy Vicarious Founders received shares of Vicarious Surgical Class B common stock equal
to the amount of shares of Legacy Vicarious Class A common stock owned by such Legacy Vicarious Founder multiplied by 3.29831 for
each share in such class of Legacy Vicarious Class A common stock that was issued and outstanding immediately prior to the Effective
Time, rounded to the nearest whole number of shares; (iii) each option to purchase shares of Legacy Vicarious common stock, whether
vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by D8 and became an
option (vested or unvested, as applicable) to purchase a number of shares of Vicarious Surgical Class A common stock equal to the
number of shares of Legacy Vicarious common stock subject to such option immediately prior to the Effective Time multiplied by 3.29831,
rounded down to the nearest whole number of shares, at an exercise price per share equal to the exercise price per share of such option
immediately prior to the Effective Time divided by 3.29831 and rounded up to the nearest whole cent; and (iv) each warrant to purchase
shares of Legacy Vicarious Class B common stock that was issued and outstanding prior to the Effective Time was assumed and converted
into a warrant exercisable for shares of Vicarious Surgical Class A common stock.
In addition, concurrently
with the execution of the Business Combination Agreement, on April 15, 2021 and September 9, 2021, D8 entered into subscription
agreements (the “Subscription Agreements”) with certain qualified institutional buyers and accredited investors (the
“PIPE Investors”), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of
14,200,000 shares of Class A common stock at a purchase price of $10.00 per share (the “PIPE Financing”).
The Offering
This Reoffer Prospectus
relates to the public offering by the selling securityholders listed in this Reoffer Prospectus,
of up to 4,828,699 shares of Class A common stock that will be acquired by or issuable to selling securityholders pursuant to a
stock option agreement or restricted stock unit agreement, as applicable, between the Company and such selling securityholder under
the 2021 Plan. Subject to the satisfaction of any conditions to vesting of the shares of Class A common stock offered hereby pursuant
to the terms of the relevant award agreements, the selling securityholders may from time to time sell, transfer or otherwise dispose of
any or all of the shares of Class A common stock covered by this Reoffer Prospectus through underwriters or dealers, directly to purchasers
(or a single purchaser) or through broker-dealers or agents. We will receive none of the proceeds from the sale of the shares of Class
A common stock by the selling securityholders. The selling securityholders will bear all sales commissions and similar expenses in connection
with this offering. We will bear all expenses of registration incurred in connection with this offering, as well as any other expenses
incurred by us in connection with the registration and offering that are not borne by the selling securityholders.
RISK FACTORS
Investing in our Class
A common stock involves a high degree of risk. Before you make a decision to buy our securities, you should carefully consider the risks
and uncertainties set forth under the heading “Risk Factors” in Item 1A of our Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 8, 2021, which are incorporated
by reference herein, and in subsequent reports we file with the SEC, together with the financial and other information contained or incorporated
by reference in this Reoffer Prospectus. Our business, operating results, financial condition or prospects could also be harmed by risks
and uncertainties not currently known to us or that we currently do not believe are material. If any of these risks actually occur, our
business, prospects, financial condition and results of operations could be materially adversely affected. In that case, the trading price
of our Common Stock could decline and you may lose all or a part of your investment. Only those investors who can bear the risk of loss
of their entire investment should invest in our Common Stock.
The risks we have described
also include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking
statements. See “Cautionary Note Regarding Forward-Looking Statements.”
USE OF PROCEEDS
We will not receive any
of the proceeds from the sale of the Shares hereunder. All of the proceeds from the sale of the Shares offered by the selling securityholders
pursuant to this Reoffer Prospectus will be sold by the selling securityholders for their respective accounts. See the sections titled
“Selling Securityholders” and “Plan of Distribution” described below.
SELLING SECURITYHOLDERS
The following table sets
forth information with respect to the selling securityholders and the shares of our Class A common stock (i) beneficially owned by the
selling securityholders, and (ii) with respect to shares of Class A common stock covered by this Reoffer Prospectus, shares subject to
options or restricted stock units held by the selling securityholders, in each case as of December 1, 2021 (the “Determination
Date”). The percentage of beneficial ownership is calculated based on 118,623,682 shares of Common Stock, comprised of 98,833,822
shares of Class A common stock and 19,789,860 shares of Class B common stock outstanding as of such date. The selling securityholders
may offer all, some or none of the shares of Class A common stock covered by this prospectus. Information concerning the selling securityholders
may change from time to time and, if necessary, we will amend or supplement this Reoffer Prospectus accordingly. We cannot give an estimate
as to the number of shares of Class A common stock that will actually be held by the selling securityholders upon termination of this
offering, because the selling securityholders may offer some or all of their Class A common stock under the offering contemplated by this
Reoffer Prospectus or acquire additional shares of Class A common stock. We cannot advise you as to whether the selling securityholders
will, in fact, sell any or all of such shares of Class A common stock.
We have determined beneficial
ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other
purpose. Shares of common stock that may be acquired by an individual or group pursuant to the exercise of options or warrants or settlement
of restricted stock units (“RSUs”) that are currently exercisable or may become exercisable or settleable are deemed
to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding
for the purpose of computing the percentage ownership of any other person shown in the table.
Unless otherwise indicated
below, the address of each selling securityholder listed in the table below is c/o Vicarious Surgical Inc., 78 Fourth Avenue, Waltham,
Massachusetts 02451, and to our knowledge, the persons and entities named in the tables have sole voting and sole investment power with
respect to all securities that they beneficially own, subject to community property laws where applicable.
Name of
|
|
Shares of Class A
Common Stock
Beneficially Owned
Prior to this Offering(1)
|
|
|
Shares of Class B
Common Stock
Beneficially Owned
Prior to this Offering
|
|
|
% of Total
Voting
Power Prior
to this
|
|
|
Number
of Shares
of Class A
Common Stock
Being
|
|
|
Number
of Shares
of Class B
Common Stock
Being
|
|
|
Shares of Class A
Common Stock
Beneficially
Owned After the
Offered Shares of
Class A Common
Stock are Sold(1)
|
|
|
Shares of Class B
Common Stock
Beneficially
Owned After the
Offered Shares of
Class B Common
Stock are Sold
|
|
|
% of Total
Voting
Power
After this
|
|
Selling Securityholder
|
|
Shares
|
|
|
Percent
|
|
|
Shares
|
|
|
Percent
|
|
|
Offering**
|
|
|
Offered(1)
|
|
|
Offered
|
|
|
Shares
|
|
|
Percent
|
|
|
Shares
|
|
|
Percent
|
|
|
Offering**
|
|
Adam Sachs(2)
|
|
|
11,914,356
|
|
|
|
10.8
|
%
|
|
|
11,329,695
|
|
|
|
57.3
|
%
|
|
|
45.9
|
%
|
|
|
584,661
|
|
|
|
—
|
|
|
|
11,329,695
|
|
|
|
10.3
|
%
|
|
|
11,329,695
|
|
|
|
57.3
|
%
|
|
|
45.8
|
%
|
David Ho(3)
|
|
|
35,709
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
|
|
35,709
|
|
|
|
—
|
|
|
|
-
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
David Styka(4)
|
|
|
1,282,821
|
|
|
|
1.3
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
|
|
1,282,821
|
|
|
|
—
|
|
|
|
-
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
Donald Tang(5)
|
|
|
8,570,709
|
|
|
|
8.7
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
1.7
|
%
|
|
|
35,709
|
|
|
|
—
|
|
|
|
8,535,000
|
|
|
|
8.6
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
1.7
|
%
|
Dror Berman(6)
|
|
|
13,805,852
|
|
|
|
14.0
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
2.8
|
%
|
|
|
35,709
|
|
|
|
—
|
|
|
|
13,770,143
|
|
|
|
13.9
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
2.8
|
%
|
June Morris(7)
|
|
|
715,177
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
|
|
715,177
|
|
|
|
—
|
|
|
|
-
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
Philip Liang(8)
|
|
|
10,372,559
|
|
|
|
10.5
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
2.1
|
%
|
|
|
35,709
|
|
|
|
—
|
|
|
|
10,336,850
|
|
|
|
10.5
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
2.1
|
%
|
Ric Fulop(9)
|
|
|
419,326
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
|
|
419,326
|
|
|
|
—
|
|
|
|
-
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
Samir Kaul(10)
|
|
|
20,991,831
|
|
|
|
21.2
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
4.2
|
%
|
|
|
35,709
|
|
|
|
—
|
|
|
|
20,956,122
|
|
|
|
21.2
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
4.2
|
%
|
Sammy Khalifa(11)
|
|
|
5,019,387
|
|
|
|
4.8
|
%
|
|
|
4,551,668
|
|
|
|
23
|
%
|
|
|
18.5
|
%
|
|
|
467,719
|
|
|
|
—
|
|
|
|
4,551,668
|
|
|
|
4.4
|
%
|
|
|
4,551,668
|
|
|
|
23
|
%
|
|
|
18.4
|
%
|
William Kelly(12)
|
|
|
1,180,450
|
|
|
|
1.2
|
%
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
|
|
1,180,450
|
|
|
|
—
|
|
|
|
-
|
|
|
|
*
|
|
|
|
—
|
|
|
|
—
|
|
|
|
*
|
|
*
|
Indicates beneficial ownership of less than 1%.
|
|
|
**
|
Percentage of total voting power represents voting power with respect to all shares of Class A common stock and Class B common stock
as a single class. Each share of Class B common stock is entitled to 20 votes per share and each share of Class A common stock is entitled
to one vote per share.
|
|
|
(1)
|
The number of shares of Class A common stock reflects all shares of Class A common stock acquired or issuable to a person pursuant
to applicable equity grants previously made irrespective of whether such grants are exercisable or vested as of the Determination Date
or will become exercisable or vested within 60 days after the Determination Date.
|
(2)
|
Consists of (i) 11,329,695 shares of Class B common stock, or Class A common stock issuable upon the conversion of Class B common
stock, as the case may be, held by Mr. Sachs, our President and Chief Executive Officer, (ii) 389,774 shares of Class A common stock issuable
upon exercise of options, and (iii) 194,887 shares of Class A common stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Sachs.
|
|
|
(3)
|
Consists of 35,709 shares of Class A common stock issuable upon settlement of 2021 Plan RSUs granted to Dr. Ho, a member of our board
of directors.
|
|
|
(4)
|
Consists of (i) 1,273,197 shares of Class A common stock issuable upon exercise of options, and (ii) 9,624 shares of Class A common
stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Styka, the Chairman and a member of our board of directors.
|
|
|
(5)
|
Consists of (i) 8,535,000 shares of Class A common stock held by D8 Sponsor LLC, and (ii) 35,709 shares of Class A common stock issuable
upon settlement of 2021 Plan RSUs granted to Mr. Tang, a member of our board of directors. David Chu and Mr. Tang are the managers of
D8 Sponsor LLC and share voting and investment discretion with respect to the shares of common stock held of record by the D8 Sponsor
LLC. Each of the Messrs. Chu and Tang disclaims any beneficial ownership of the securities held by D8 Sponsor LLC other than to the extent
of any pecuniary interest he may have therein, directly or indirectly. The business address of D8 Sponsor LLC is Unit 1008, 10/F, Champion
Tower, 3 Garden Road, Central, Hong Kong.
|
|
|
(6)
|
Consists of (i) 13,770,143 shares of Class A common stock held by Innovation Endeavors III LP (“Innovation Endeavors”),
and (ii) 35,709 shares of Class A common stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Berman, a member of our board
of directors. Mr. Berman is a managing partner at Innovation Endeavors, and as such may be deemed to have voting and investment control
over the shares held by Innovation Endeavors. The business address of Innovation Endeavors is 1845 El Camino Real, Palo Alto, CA 94306.
|
|
|
(7)
|
Consists of (i) 663,689 shares of Class A common stock issuable upon exercise of options, and (ii) 51,488 shares of Class A common
stock issuable upon settlement of 2021 Plan RSUs granted to Ms. Morris, our Chief Legal Officer, General Counsel and Secretary.
|
|
|
(8)
|
Consists of (i) 10,036,850 shares of Class A common stock held by Chelvey International Limited (“Chelvey”). (ii) 300,000
shares of Class A common stock held by E15 Fund Advisors (HK) Limited (“E15 Fund Advisors”), and (iii) 35,709 shares of Class
A common stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Liang, a member of our board of directors. Chelvey is an entity
affiliated with E15 Fund II, LP (“E15”). Mr. Liang is the managing partner for E15. Shrikant Patnaik is a principal for E15.
Each of Messrs. Liang and Patnaik share voting and investment discretion with respect to the shares of Class A common stock held of record
by E15, and as such may be deemed to have voting and investment control over the shares held by E15 and the entities affiliated with E15.
Mr. Liang is the managing partner for E15 Fund Advisors, and as such may be deemed to have voting and investment control over the shares
held by E15 Fund Advisors and the entities affiliated with E15 Fund Advisors. The business address of E15 is Ogier Global (Cayman) Limited,
89 Nexus way, Camana Bay, Grand Cayman, KY1 - 9009, Cayman Islands. The business address of E15 Fund Advisors is RMS2102 - 03 China Insurance
Group Bldg., 141 Des Voeux Rd., Central, Hong Kong.
|
|
|
(9)
|
Consists of (i) 409,702 shares of Class A common stock issuable upon exercise of options, and (ii) 9,624 shares of Class A common
stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Fulop, a member of our board of directors.
|
|
|
(10)
|
Consists of (i) 7,896,787 shares of Class A common stock held by Khosla Ventures Seed C, LP (“Khosla Ventures Seed C”),
(ii) 13,059,335 shares of Class A common stock held by Khosla Ventures V, LP (“Khosla Ventures V”), and (iii) 35,709 shares
of Class A common stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Kaul, a member of our board of directors. Khosla Ventures
Seed Associates C, LLC (“KVA Seed C”) is the general partner of Khosla Ventures Seed C. Khosla Ventures Associates V, LLC
(“KVA V”) is the general partner of Khosla Ventures V. Vinod Khosla is the managing member of VK Services, LLC (“VK
Services”), which is the sole manager of KVA Seed C and KVA V. Each of KVA Seed C, VK Services and Vinod Khosla may be deemed to
possess voting and investment control over such securities held by Khosla Ventures Seed C, and each of KVA Seed C, VK Services and Vinod
Khosla may be deemed to have indirect beneficial ownership of such securities held by Khosla Ventures Seed C. Each of KVA V, VK Services
and Vinod Khosla may be deemed to possess voting and investment control over such securities held by Khosla Ventures V, and each of KVA
V, VK Services and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by Khosla Ventures V. Each
of KVA Seed C, KVA V, VK Services and Vinod Khosla disclaims beneficial ownership of such shares except to the extent of his or its respective
pecuniary interests therein. Mr. Kaul is a General Partner and Managing Director of Khosla Ventures, LLC. Mr. Kaul disclaims any beneficial
ownership of the securities held by Khosla Ventures Seed C and Khosla Ventures V other than to the extent of any pecuniary interest he
may have therein, directly or indirectly. The business address of each of the reporting persons is 2121 Sand Hill Road, Menlo Park, CA
94025.
|
|
|
(11)
|
Consists of (i) 4,551,668 shares of Class B common stock,
or Class A common stock issuable upon the conversion of Class B common stock, as the case may be, held by Mr. Khalifa, our Chief Technology
Officer, (ii) 311,819 shares of Class A common stock issuable upon exercise of options, and (iii) 155,900 shares of Class A common stock
issuable upon settlement of 2021 Plan RSUs granted to Mr. Khalifa.
|
(12)
|
Consists of (i) 1,128,388 shares of Class A common stock issuable upon exercise of options, and (ii) 52,062 shares of Class A common
stock issuable upon settlement of 2021 Plan RSUs granted to Mr. Kelly, our Chief Financial Officer and Treasurer.
|
PLAN OF DISTRIBUTION
We are registering the
Shares covered by this Reoffer Prospectus to permit the selling securityholders to conduct public secondary trading of the Shares from
time to time after the date of this Reoffer Prospectus. We will not receive any of the proceeds from the sale of the Shares offered by
this Reoffer Prospectus. The aggregate proceeds to the selling securityholders from the sale of the Shares will be the purchase price
of the Shares less any discounts and commissions. We will not pay any brokers’ or underwriters’ discounts and commissions
in connection with the registration and sale of the Shares covered by this Reoffer Prospectus. The selling securityholders reserve the
right to accept and, together with their respective agents, to reject, any proposed purchases of the Shares to be made directly or through
agents.
The Shares offered by
this Reoffer Prospectus may be sold from time to time to purchasers:
|
●
|
directly by the selling securityholders;
|
|
●
|
through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, commissions or agent’s
commissions from the selling securityholders or the purchasers of the Shares; or
|
|
●
|
through a combination of any of these methods of sale.
|
Any underwriters, broker-dealers
or agents who participate in the sale or distribution of the Shares may be deemed to be “underwriters” within the meaning
of the Securities Act. As a result, any discounts, commissions or concessions received by any such broker-dealer or agents who are deemed
to be underwriters will be deemed to be underwriting discounts and commissions under the Securities Act. Underwriters are subject to the
prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities under the Securities Act and
the Exchange Act. We will make copies of this Reoffer Prospectus available to the selling securityholders for the purpose of satisfying
the prospectus delivery requirements of the Securities Act. To our knowledge, there are currently no plans, arrangements or understandings
between the selling securityholders and any underwriter, broker-dealer or agent regarding the sale of the Shares by the selling securityholders.
The Shares may be sold
in one or more transactions at:
|
●
|
prevailing market prices at the time of sale;
|
|
●
|
prices related to such prevailing market prices;
|
|
●
|
varying prices determined at the time of sale; or
|
These sales may be effected
in one or more transactions:
|
●
|
on any national securities exchange or quotation service on which the Shares may be listed or quoted at the time of sale, including
NYSE;
|
|
●
|
in the over-the-counter market;
|
|
●
|
in transactions otherwise than on such exchanges or services or in the over-the-counter market;
|
|
●
|
through trading plans entered into by the selling securityholder pursuant to Rule 10b5-1 under the Exchange Act that are in place
at the time of an offering pursuant to this Reoffer Prospectus and any applicable prospectus supplement hereto that provide for periodic
sales of their securities on the basis of parameters described in such trading plans;
|
|
●
|
any other method permitted by applicable law; or
|
|
●
|
through any combination of the foregoing.
|
These transactions may
include block transactions or crosses. Crosses are transactions in which the same broker acts as an agent on both sides of the trade.
At the time a particular
offering of the Shares is made, a prospectus supplement, if required, will be distributed, which will set forth the name of the selling
securityholders, the aggregate amount of Shares being offered and the terms of the offering, including, to the extent required, (1) the
name or names of any underwriters, broker-dealers or agents, (2) any discounts, commissions and other terms constituting compensation
from the selling securityholders and (3) any discounts, commissions or concessions allowed or reallowed to be paid to broker-dealers.
The selling securityholders
will act independently of us in making decisions with respect to the timing, manner, and size of each resale or other transfer. There
can be no assurance that the selling securityholders will sell any or all of the Shares under this Reoffer Prospectus. Further, we cannot
assure you that the selling securityholders will not transfer, distribute, devise or gift the Shares by other means not described in this
Reoffer Prospectus. In addition, any Shares covered by this Reoffer Prospectus that qualify for sale under Rule 144 of the Securities
Act may be sold under Rule 144 rather than under this Reoffer Prospectus. The Shares may be sold in some states only through registered
or licensed brokers or dealers. In addition, in some states the Shares may not be sold unless they have been registered or qualified for
sale or an exemption from registration or qualification is available and complied with.
The selling securityholders
and any other person participating in the sale of the Shares will be subject to the Exchange Act. The Exchange Act rules include, without
limitation, Regulation M, which may limit the timing of purchases and sales of any of the Shares by the selling securityholders and any
other person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the Shares to engage in
market-making activities with respect to the particular securities being distributed. This may affect the marketability of the Shares
and the ability of any person or entity to engage in market-making activities with respect to the Shares.
Once sold under the registration
statement of which this Reoffer Prospectus forms a part, the shares of Class A common stock will be freely tradable in the hands of persons
other than our affiliates.
LEGAL MATTERS
The validity of the Shares
offered hereby has been passed upon by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston,
Massachusetts.
INFORMATION INCORPORATED
BY REFERENCE
The following documents filed by the Registrant
with the Commission are incorporated herein by reference:
|
(a)
|
The prospectus filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act, on October 25, 2021,
relating to the Registration Statement on Form S-1, as amended (File No. 333-260281), (excluding Items I and II in the “Index
to Financial Statements” on page F-1 thereof and the audited and unaudited financial statements of D8 Holdings Corp. set forth on
pages F-2 to F-45 thereof, which are not incorporated herein by reference);
|
|
(b)
|
The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Commission on May 24, 2021,
the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the Commission on August 12, 2021,
and the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Commission on November
8, 2021;
|
|
(c)
|
The Registrant’s Current Reports on Form 8-K or 8-K/A as filed with the Commission on April 15, 2021, May 21, 2021, August 24, 2021, August 26, 2021, September 7, 2021, September 10, 2021, September 14, 2021, September 15, 2021, September 23, 2021, September 23, 2021, October 20, 2021, and November 8, 2021;
|
|
(d)
|
The description of the Registrant’s securities contained in the Registrant’s registration
statement on Form 8-A (File No. 001-39384), filed by the Registrant with the Commission under Section 12(b) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), on July 13, 2020, including any amendments or reports filed for the purpose
of updating such description.
|
All reports and other documents
filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current
Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the
filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities
then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports
and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration
statement.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We file annual, quarterly
and current reports, proxy statements and other documents with the SEC under the Exchange Act. Our SEC filings are available to the public
over the Internet at the SEC’s website at http://www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC
pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge by linking directly from our website at https://www.vicarioussurgical.com.
These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to, the
SEC. The information on, or that can be accessed through, our website is not part of this Reoffer Prospectus.
We will provide without charge
to each person, including any beneficial owner, to whom a copy of this Reoffer Prospectus is delivered, upon written or oral request of
any such person, a copy of any and all of the information that has been incorporated by reference in this Reoffer Prospectus but not delivered
with the Reoffer Prospectus other than the exhibits to those documents, unless the exhibits are specifically incorporated by reference
into the information that this Reoffer Prospectus incorporates. Requests for documents should be directed to Vicarious Surgical Inc.,
Attention: Legal Department, 78 Fourth Avenue, Waltham, Massachusetts 02451, (617) 868-1700.
Vicarious Surgical, Inc.
4,828,699 Shares of Class A Common Stock
REOFFER PROSPECTUS
December 17, 2021
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
|
Item 3.
|
Incorporation of Documents by Reference.
|
The following documents filed by the Registrant
with the Commission are incorporated herein by reference:
|
(c)
|
The prospectus filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act, on October 25, 2021,
relating to the Registration Statement on Form S-1, as amended (File No. 333-260281), (excluding Items I and II in the “Index
to Financial Statements” on page F-1 thereof and the audited and unaudited financial statements of D8 Holdings Corp. set forth on
pages F-2 to F-45 thereof, which are not incorporated herein by reference);
|
|
(d)
|
The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Commission on May 24, 2021,
the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the Commission on August 12, 2021,
and the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Commission on November
8, 2021;
|
|
(c)
|
The Registrant’s Current Reports on Form 8-K or 8-K/A as filed with the Commission on April 15, 2021, May 21, 2021, August 24, 2021, August 26, 2021, September 7, 2021, September 10, 2021, September 14, 2021, September 15, 2021, September 23, 2021, September 23, 2021, October 20, 2021, and November 8, 2021;
|
|
(d)
|
The description of the Registrant’s securities contained in the Registrant’s registration
statement on Form 8-A (File No. 001-39384), filed by the Registrant with the Commission under Section 12(b) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), on July 13, 2020, including any amendments or reports filed for the purpose
of updating such description.
|
All reports and other documents
filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current
Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the
filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities
then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports
and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration
statement.
|
Item 4.
|
Description of Securities.
|
Not applicable.
|
Item 5.
|
Interests of Named Experts and Counsel.
|
The validity of the issuance of the shares of Class
A common stock registered under this Registration Statement has been passed upon for the Registrant by Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and members of that firm own an aggregate of approximately 150,551
shares of Class A common stock of the Registrant.
|
Item 6.
|
Indemnification of Directors and Officers.
|
Section 145 of the Delaware
General Corporation Law (the “DGCL”), permits a corporation to indemnify its directors and officers against expenses,
including attorneys’ fees, judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection
with any action, suit or proceeding brought by third parties. The directors or officers must have acted in good faith and in a manner
they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or
proceeding, had no reason to believe their conduct was unlawful. In a derivative action, an action only by or in the right of the corporation,
indemnification may be made only for expenses, including attorney’s fees, actually and reasonably incurred by directors and officers
in connection with the defense or settlement of an action or suit, and only with respect to a matter as to which they acted in good faith
and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation. No indemnification shall be
made if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the
action or suit was brought determines upon application that the defendant officers or directors are fairly and reasonably entitled to
indemnity for such expenses despite such adjudication of liability. The amended and restated certificate of incorporation and the amended
and restated bylaws of the registrant provide that the registrant may indemnify its directors, officers, employees or agents to the fullest
extent permitted by applicable law.
Section 102(b)(7) of the DGCL
permits a corporation to provide in its charter that a director of the corporation shall not be personally liable to the corporation or
its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s
duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct
or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock purchases or redemptions or (4) for any transaction
from which the director derived an improper personal benefit. The current certificate of incorporation of the registrant provide for such
limitation of liability.
We have entered into indemnification
agreements with each of our directors and executive officers in which we have agreed to indemnify and hold harmless, and also advance
expenses as incurred, to the fullest extent permitted under applicable law, against all expenses, losses and liabilities incurred by the
indemnitee or on the indemnitee’s behalf arising from the fact that such person is or was a director, officer, employee or agent
of our company or our subsidiaries.
The indemnification rights
set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute,
our amended and restated certificate of incorporation, our amended and restated bylaws, any agreement, any vote of stockholders or disinterested
directors or otherwise.
We maintain standard policies
of insurance that provide coverage (1) to our directors and officers against loss rising from claims made by reason of breach of duty
or other wrongful act and (2) to us with respect to indemnification payments that we may make to such directors and officers.
|
Item 7.
|
Exemption from Registration Claimed.
|
Not applicable.
Exhibit
Number
|
|
Exhibit Description
|
|
Filed
Herewith
|
|
Incorporated by
Reference herein from
Form or Schedule
|
|
Filing Date
|
|
SEC File/
Reg.
Number
|
4.1
|
|
Certificate of Incorporation of Vicarious Surgical Inc.
|
|
|
|
Form 8-K
(Exhibit 3.1)
|
|
9/23/2021
|
|
001-39384
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Amended and Restated Bylaws of Vicarious Surgical Inc.
|
|
|
|
Form 8-K
(Exhibit 3.2)
|
|
9/23/2021
|
|
001-39384
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
Specimen Class A Common Stock Certificate.
|
|
|
|
Form 8-K
(Exhibit 4.1)
|
|
9/23/2021
|
|
001-39384
|
|
|
|
|
|
|
|
|
|
|
|
4.4
|
|
Warrant Agreement, dated as of July 14, 2020, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.) and Continental Stock Transfer & Trust Company
|
|
|
|
Form 8-K
(Exhibit 4.1)
|
|
7/17/2020
|
|
001-39384
|
|
|
|
|
|
|
|
|
|
|
|
5.1
|
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1
|
|
Consent of Deloitte & Touche LLP, independent registered public accounting firm of Vicarious Surgical Inc.
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.2
|
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1
|
|
Power of Attorney (included on the signature page hereof)
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1+
|
|
Vicarious Surgical Inc. 2021 Equity Incentive Plan, and forms of agreement thereunder
|
|
|
|
Form 8-K
(Exhibit 10.10)
|
|
9/23/2021
|
|
001-39384
|
|
+
|
Denotes management contract or compensatory plan or arrangement
|
The undersigned registrant hereby undertakes:
|
(1)
|
To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement:
|
|
(i)
|
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended;
|
|
(ii)
|
To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price
set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
|
|
(iii)
|
To include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement.
|
|
(2)
|
That, for the purpose of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
|
|
(3)
|
To remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.
|
|
(4)
|
That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus
filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying
on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of
the registration statement or made in any such document immediately prior to such date of first use.
|
|
(5)
|
That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser
in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will
be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
|
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424;
|
|
(ii)
|
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant
or used or referred to by the undersigned registrant;
|
|
(iii)
|
The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
(iv)
|
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
Insofar as indemnification for liabilities arising
under the Securities may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed
in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in
the Securities Act and will be governed by the final adjudication of such issue.
Signatures
Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Waltham, State of Massachusetts, on December 17, 2021.
|
VICARIOUS SURGICAL INC.
|
|
|
|
|
By:
|
/s/ Adam Sachs
|
|
|
Adam Sachs
|
|
|
Chief Executive Officer
|
POWER OF ATTORNEY
Each person whose signature appears below constitutes
and appoints each of Adam Sachs and William Kelly, acting alone or together with another attorney-in-fact, as his or her true and lawful
attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead,
in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement
(and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act (and all further
amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to
all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and
agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act, this registration statement has been signed by the following persons in the capacities and on the dated indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Adam Sachs
|
|
Chief Executive Officer, President and
|
|
December 17, 2021
|
Adam Sachs
|
|
Director
|
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ William Kelly
|
|
Chief Financial Officer and Treasurer
|
|
December 17, 2021
|
William Kelly
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ David Styka
|
|
Chairman
|
|
December 17, 2021
|
David Styka
|
|
|
|
|
|
|
/s/ Sammy Khalifa
|
|
Director
|
|
December 17, 2021
|
Sammy Khalifa
|
|
|
|
|
|
|
/s/ Samir Kaul
|
|
Director
|
|
December 17, 2021
|
Samir Kaul
|
|
|
|
|
|
|
/s/ Philip Liang
|
|
Director
|
|
December 17, 2021
|
Philip Liang
|
|
|
|
|
|
/s/ Ric Fulop
|
|
Director
|
|
December 17, 2021
|
Ric Fulop
|
|
|
|
|
|
|
/s/ Dror Berman
|
|
Director
|
|
December 17, 2021
|
Dror Berman
|
|
|
|
|
|
|
/s/ Donald Tang
|
|
Director
|
|
December 17, 2021
|
Donald Tang
|
|
|
|
|
|
|
/s/ David Ho
|
|
Director
|
|
December 17, 2021
|
David Ho
|
|
II-5
D8 (NYSE:DEH)
Historical Stock Chart
From Aug 2024 to Sep 2024
D8 (NYSE:DEH)
Historical Stock Chart
From Sep 2023 to Sep 2024